knowledge -WSS

knowledge

author：focus 2025-08-12 09:08:26 - browse：1

Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Roche to buy Carmot Therapeutics, developer of obesity drugs

WSS

FDA approves world's first CRISPR

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Leukemia patients are helped by Syndax's new type of therapy

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

He's a Nobel laureate. Critics say he was misleading on Covid

explore

knowledge

focus

Alkermes shareholders re

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Duchenne breakthrough therapy leaves behind pioneering families

STAT letters to the editor on burnt

Affirmative action in medical school literally saved lives

What PEPFAR has meant on the ground in Ukraine

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

In diabetes hearing, Sanders takes on a new foe: food makers

hotspot

SCOTUS to consider access to abortion pill mifepristone

SCOTUS to consider access to abortion pill mifepristone

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

6 phony surgeries that take placebo to the extreme

Leukemia patients are helped by Syndax's new type of therapy

What causes an itch? Researchers may have solved the mystery

hotspot

hotspot

hotspot

knowledge